Elsevier

Biochemical Pharmacology

Volume 74, Issue 7, 1 October 2007, Pages 949-959
Biochemical Pharmacology

Phospholipase A2 as targets for anti-cancer drugs

https://doi.org/10.1016/j.bcp.2007.04.021Get rights and content

Abstract

Phospholipase A2 (PLA2) are esterases that cleave glycerophospholipids to release fatty acids and lysophospholipids. Inhibition of PLA2 alters cancer cell growth and death in vitro and PLA2 expression is increased in breast, lung, and prostate cancers compared to control tissues. Thus, PLA2 may be novel targets for chemotherapeutics. However, PLA2 are a diverse family of enzymes, encompassing 19 members. The selectivity of these individual PLA2 for phospholipids varies, as does their location within the cell, and tissue expression. Thus, their role in cancer may also vary. This review summarizes the expression of individual PLA2 in cancers, focuses on the potential mechanisms by which these esterases mediate carcinogenesis, and suggests that select PLA2 isoforms may be targets for anti-cancer drugs.

Introduction

Phospholipase A2 (PLA2) are esterases that cleave glycerophospholipids at the sn-2 ester bond to release a fatty acid and lysophospholipid ([1], [2]; Fig. 1). The activity and expression of several PLA2 isoforms are increased in several human cancers [3], [4], [5], [6], [7], [8], [9], [10], [11], suggesting that these enzymes may be targets for anti-cancer drugs [5]. In order to prove this hypothesis more information is needed about the role of PLA2 in the mechanisms of carcinogenesis.

A major mechanism by which PLA2 may mediate carcinogenesis is the release of arachidonic acid, a 20-carbon fatty acid containing 4 double bonds, from glycerophospholipids. Once released, arachidonic acid is metabolized by multiple enzymes into several molecules, most of which induce cancer cell growth and proliferation in vitro[12]. In addition, PLA2 may also mediate carcinogenesis by releasing lysophospholipids (Fig. 1), which can induce cell growth via their metabolism to lysophosphatidic acid (LPA) [13], [14]. Thus, multiple mechanisms exist by which PLA2 can participate in the development of cancer.

PLA2 inhibitors are attractive anti-cancer targets as they would theoretically decrease the formation of both arachidonic acid and LPA congruently. This would eliminate the shifting of arachidonic acid to alternate pathways, possibly decreasing adverse side effects associated with arachidonic acid metabolism inhibitors [5]. However, PLA2 are a diverse family of enzymes with at least 19 different individual isoforms [2], some of which have important physiological roles [1], [15]. Thus, general inhibitors that target all PLA2 may not be practical. Therefore, more studies are needed focusing on the development of inhibition strategies for individual PLA2 isoforms. Such studies would enhance the development of PLA2 inhibitors for treatment of cancer.

Section snippets

Classification of PLA2

PLA2 are broadly defined into three different classes; secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2), and Ca2+-independent PLA2 (iPLA2) [1], [2]. sPLA2 are the oldest class of PLA2. They are found throughout nature, and were originally characterized in snake and bee venom [1]. They range in size from 13 to 19 kDa, typically require Ca2+ for their activity, and utilize histidine to hydrolyze the sn-2 ester bond of the glycerol backbone [2]. cPLA2 and iPLA2 are larger in size, typically 66–90 kDa,

PLA2 expression in human cancers

Several studies demonstrate increased expression of PLA2 in human cancers [3], [4], [5], [6], [7], [8], [9], [10], [11]. However, with the exception of Group IIA PLA2 (sPLA2), the exact roles for many of these PLA2, and their contribution towards carcinogenesis are not well understood. Further, many studies typically report the expression of a specific class of PLA2 (sPLA2, cPLA2, or iPLA2), but information regarding the expression of individual group members is lacking, with some exceptions.

Roles of PLA2 in the mechanisms of tumor formation and cancer cell growth

The roles of PLA2 in the mechanisms of carcinogenesis are diverse and somewhat controversial. They include the generation of inflammatory mediators that may to tumor formation [58], [62]. In addition, arachidonic acid and lysophospholipids can be metabolized to several molecules that induce cancer cell growth [23], [27], [28], [40], [78], [79]. Finally, the ability of select PLA2 to maintain membrane glycerophospholipids may also contribute to cancer cell growth [27], [28].

Regardless of the

Conclusion

The question can be posed if enzymes that mediate the formation of arachidonic acid and lysophospholipid metabolites are better anti-cancer targets than PLA2. This is a valid question and these pathways certainly deserve further study. However, some inhibitors of arachidonic acid metabolism, such as COX-2 inhibitors, have severe and unpredictable cardiovascular side effects [86]. This toxicity may be a result of the fact that if arachidonic acid is not metabolized by COX-2 its metabolism may be

Acknowledgements

This work was supported by a Georgia Cancer Coalition Distinguished Scholar Grant. I would like to also acknowledge Dr. Shelly Hooks and Dr. Rusty Arnold for their expertise in preparing this manuscript and Brianna Peterson, Bin Sun, and Xiaoling Zhang for their aid in proof reading.

References (108)

  • C.M. Jenkins et al.

    Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities

    J Biol Chem

    (2004)
  • A.A. Farooqui et al.

    Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders

    Brain Res Bull

    (1999)
  • J.V. Bonventre

    Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity

    J Lipid Mediat Cell Signal

    (1997)
  • G. Atsumi et al.

    Fas-induced arachidonic acid release is mediated by Ca2+-independent phospholipase A2 but not cytosolic phospholipase A2, which undergoes proteolytic inactivation

    J Biol Chem

    (1998)
  • S. Bao et al.

    Effects of Stable Suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells

    J Biol Chem

    (2006)
  • W.E. Longo et al.

    The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells

    J Surg Res

    (1999)
  • S. Hassan et al.

    Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth

    Regul Pept

    (2006)
  • V. Teslenko et al.

    Macrophage arachidonate release via both the cytosolic Ca(2+)-dependent and -independent phospholipases is necessary for cell spreading

    Biochim Biophys Acta

    (1997)
  • S. Ramanadham et al.

    Glucose-responsitivity and expression of an ATP-stimulatable, Ca(2+)-independent phospholipase A2 enzyme in clonal insulinoma cell lines

    Biochim Biophys Acta

    (1997)
  • J. Balsinde et al.

    Antisense inhibition of group VI Ca2+-independent phospholipase A2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages

    J Biol Chem

    (1997)
  • J. Balsinde et al.

    Function and inhibition of intracellular calcium-independent phospholipase A2

    J Biol Chem

    (1997)
  • J. Balsinde et al.

    Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages

    J Biol Chem

    (1996)
  • G.Y. Sun et al.

    Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases

    J Lipid Res

    (2004)
  • I. Kudo et al.

    Phospholipase A2 enzymes

    Prostaglandins Other Lipid Mediat

    (2002)
  • J.D. Clark et al.

    A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP

    Cell

    (1991)
  • G. Atsumi et al.

    Distinct roles of two intracellular phospholipase A2s in fatty acid release in the cell death pathway. Proteolytic fragment of type IVA cytosolic phospholipase A2alpha inhibits stimulus-induced arachidonate release, whereas that of type VI Ca2+-independent phospholipase A2 augments spontaneous fatty acid release

    J Biol Chem

    (2000)
  • A. Sapirstein et al.

    Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells

    J Biol Chem

    (1996)
  • E.J. Ackermann et al.

    Mammalian calcium-independent phospholipase A2

    Biochim Biophys Acta

    (1995)
  • Y.C. Lio et al.

    Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate

    Biochim Biophys Acta

    (1996)
  • G.R. Kinsey et al.

    Identification and distribution of endoplasmic reticulum iPLA2

    Biochem Biophys Res Commun

    (2005)
  • C.M. Jenkins et al.

    Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPlA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s

    J Biol Chem

    (2002)
  • C. Dentan et al.

    Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase

    Biochim Biophys Acta

    (1996)
  • X. Su et al.

    Small interfering RNA knockdown of calcium-independent phospholipases A2 beta or gamma inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes

    J Biol Chem

    (2004)
  • Z. Ying et al.

    Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma

    Biochim Biophys Acta

    (1994)
  • M. MacPhee et al.

    The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia

    Cell

    (1995)
  • D. Wendum et al.

    COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas

    Mod Pathol

    (2003)
  • Z. Ma et al.

    Cloning and expression of a group IV cytosolic Ca2+-dependent phospholipase A2 from rat pancreatic islets. Comparison of the expressed activity with that of an islet group VI cytosolic Ca2+-independent phospholipase A2

    Biochim Biophys Acta

    (1998)
  • L. Zhang et al.

    The effect of inhibition of Ca2+-independent phospholipase A2 on chemotherapeutic-induced death and phospholipid profiles in renal cells

    Biochem Pharmacol

    (2005)
  • J.V. Bonventre

    Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity

    J Lipid Mediat Cell Signal

    (1996)
  • J.Y. Liou et al.

    Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance

    Exp Cell Res

    (2005)
  • Y.J. Suh et al.

    Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells

    Surgery

    (2005)
  • M. Murakami et al.

    Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2)

    J Biol Chem

    (2005)
  • L. Xu et al.

    A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth

    J Biol Chem

    (2006)
  • D. Wendum et al.

    Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer

    Mod Pathol

    (2005)
  • W.G. Jiang et al.

    Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer

    Prostaglandins Leukot Essent Fatty Acids

    (2003)
  • J.H. Kim et al.

    Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein

    Biochim Biophys Acta

    (2005)
  • R.E. Carraway et al.

    Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells

    Prostaglandins Leukot Essent Fatty Acids

    (2006)
  • J. Ghosh

    Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase

    Biochem Biophys Res Commun

    (2004)
  • P.A. Nony et al.

    15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK

    J Biol Chem

    (2005)
  • H. Kuwata et al.

    Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway

    J Biol Chem

    (2005)
  • Cited by (143)

    • Crosstalk signaling of phospholipase A2 (PLA2) in lung cancer

      2023, Phospholipases in Physiology and Pathology: Volumes 1-7
    • Anticancer role of natural compounds targeting phospholipase A2

      2023, Phospholipases in Physiology and Pathology: Volumes 1-7
    • Highlighting the role of phospholipase A2 and noncoding RNA in colorectal cancer

      2023, Phospholipases in Physiology and Pathology: Volumes 1-7
    • Role of phospholipase A2 in squamous cell carcinoma and breast cancer

      2023, Phospholipases in Physiology and Pathology: Volumes 1-7
    View all citing articles on Scopus
    View full text